Weekly Longevity...By Klim
Longevity & Preventative Health: Week of June 17, 2026
Funding & M&A
REMEDY raised a $20M Series A led by L Catterton (June 11, 2026). The clinical-skincare brand, co-founded by board-certified dermatologist Dr. Muneeb Shah, drew the LVMH-backed consumer fund as lead, with existing investor Norwest Venture Partners and new investor Sonoma Brands Capital participating. Proceeds fund clinical research, product development, team hiring, and growth across direct-to-consumer, Amazon, and Target. Source: Business Wire; Beauty Independent; Cosmetics Business.
Rylo raised $85M and rebranded from Nagish (June 9, 2026). The AI communication company building accessibility tools for the Deaf and hard-of-hearing community — real-time captioning, sign-language translation, and workplace-accessibility features — was valued at roughly $500M and crossed $100M in total funding. Canaan led, with General Catalyst’s Customer Value Fund, Vertex Ventures, and Contour participating. Source: Business Wire; Calcalist; FinSMEs.
HMNC Brain Health announced a $50M first close of its Series B (June 15, 2026). The Munich-based clinical-stage neuroscience company said the financing, led by MEDICE with the Maschmeyer Group participating, funds Phase 3 readiness for Ketabon, an oral prolonged-release ketamine for treatment-resistant depression, plus continued work on Nelivabon, a biomarker-guided therapy for biologically defined depression. Source: Tech Startups venture roundup (June 15); company release.
My Lens / Pattern to watch
A quieter funding week, and the capital that moved went to credibility signals rather than scale: a dermatologist-led skincare brand backed by luxury’s strategic fund, a depression program tied to a biomarker, an accessibility platform with a clinical use case. After the megadeal-heavy spring, the marginal dollar this week wanted a defensible reason to believe — clinical authorship, a measurable endpoint, a verified user need.
Breakthroughs & Research
Nature Communications published the first randomized evidence that semaglutide slows epigenetic aging (June 9, 2026). In a 32-week, double-blind, placebo-controlled Phase 2b trial in adults with HIV-associated lipohypertrophy (semaglutide n=45; placebo n=39), participants on the GLP-1 agonist showed roughly a 9% slowing of biological aging pace on the DunedinPACE epigenetic clock versus placebo, with improvements in methylation markers linked to inflammation and to blood, brain, heart, liver, kidney, and metabolic health. Researchers caution this is a single, specific population and not a general-aging claim. Source: Nature Communications (s41467-026-72861-3); UC San Diego Today; Medical News Today; MedicalXpress.
A 2026 review formalized the bidirectional link between GLP-1 drugs and the gut microbiome (British Journal of Clinical Pharmacology). The paper (Kamath et al.) synthesizes evidence that gut microbial metabolites — short-chain fatty acids and bile-acid derivatives — modulate endogenous GLP-1 secretion, while GLP-1 receptor agonists in turn reshape microbial composition, suggesting some metabolic benefit runs through the microbiome rather than the incretin pathway alone. Source: British Journal of Clinical Pharmacology (Wiley, 2026).
My Lens / Pattern to watch
The semaglutide-aging result is the cleanest data point yet for treating GLP-1s as gerotherapeutics rather than weight drugs — but it is one small trial in one specific population, and the honest read is “signal, not proof.” The commercial temptation will be to market “slows aging” off a 9% DunedinPACE shift; the defensible position is to wait for replication in general populations before making that claim to a consumer.
New Openings
Canyon Ranch debuts a dedicated Longevity Retreat in Tucson (June 21–25, 2026). The flagship resort is formalizing longevity into a structured multi-day program — diagnostics, movement, nutrition, and recovery across more than 30 daily activities — priced at roughly $20,000 per person (about $36,000 per couple), a sign that legacy destination spas are packaging “longevity” as a premium, protocol-led product rather than a spa add-on. Source: Canyon Ranch.
Life Time prepares to open Life Time Paradise Valley near Phoenix (2026). The roughly 92,000-square-foot athletic country club extends Life Time’s large-format expansion and its push into recovery and longevity-adjacent amenities; the company is also building a smaller midtown-Manhattan performance-and-content location. Verify note: opening targeted to 2026; exact opening day within the period not confirmed. Source: Athletech News; Barchart/company materials.
New Launches
Oura began rolling out AI-enabled care with Counsel Health inside the Oura app (June 16, 2026). Through Oura Labs, eligible members in 43 U.S. states can engage Counsel’s medical AI chat (included in membership) and connect to Counsel’s licensed physicians for visits and treatment at extra cost; Oura is also adding Health Records import per its CMS Health Tech Ecosystem interoperability pledge. Counsel is an AI-native primary-care company pairing medical AI with physicians. Source: Oura (The Pulse blog); Modern Healthcare.
Samsung began rolling out a redesigned Samsung Health app (from June 8, 2026). The app now organizes data around five pillars — Sleep, Activity, Nutrition, Mindfulness, Vitals — and surfaces an AI Energy Score and daily tips on the home screen. It also expands longevity-flavored tracking: the Antioxidant Index gains history and trend charts, and an AGEs (advanced glycation end-products) Index can run automatically during sleep to show longer-term lifestyle patterns. Source: TechRepublic; Samsung.
My Lens / Pattern to watch
Oura putting an AI-plus-physician front door inside the ring app is the clearest move yet from “tracker” to “care entry point” — the wearable now wants to be where a health concern becomes a clinical encounter. Combined with Samsung surfacing AGEs and antioxidant metrics, the consumer device is quietly annexing the language and the workflow that longevity clinics charge for.
Conferences & Events
Forward-looking — confirmed events in the next 30 days.
HLTH Europe — June 15–18, RAI Amsterdam. Major European digital-health and healthtech gathering with a dedicated startup track.
Longevity Summit Dublin — June 24–26, Trinity College Dublin. Longevity science and biotech.
The Longevity Show + Scaling Health & Longevity Conference — June 26–27, Tobacco Dock, London. Consumer-plus-trade longevity festival, including a Women’s Health Summit track.
Healthy Longevity Talent Incubator (HLTI) — June 29 – July 10, National University of Singapore. Early-career healthy-longevity training program.
World Conference on Gerontology and Geriatrics — July 5–8, Amsterdam. Theme: aging well in a globalized world.
Opinion & Long Reads
The Boston Globe — “Wearables, and the flood of data they generate, inch closer to entering the clinic” (June 10, 2026). The feature examines how Whoop, Oura, and others are pushing consumer biometrics toward clinical use, and the open questions that follow: data validation, clinician workflow burden, liability, and whether physicians can act on continuous signals. It is a useful counterweight to the marketing as wearables reposition from lifestyle tracker to care input. Source: The Boston Globe.
the5krunner — “Whoop killers: which brands will launch a screenless band?” (June 11, 2026). A trade analysis of the screenless-band race set off by Google’s Fitbit Air, weighing which incumbents (Garmin, Samsung, Amazfit, Polar) are positioned to ship a subscription-light Whoop competitor and what that means for wearable unit economics. Source: the5krunner.
Other Notable News
FDA authorized Colorado’s program to import prescription drugs from Canada (June 15, 2026). The state’s importation program covers an initial set of about 20 medicines — reported to include Ozempic and Rinvoq — with projected savings of roughly 20–60% on covered drugs. It is one of the first state importation programs to clear federal review and a potential pressure point on U.S. cash-pay pricing for high-demand GLP-1 and specialty drugs. Source: FDA; KRDO.
FDA novel-approval watch (June 10–17, 2026). No novel-drug approvals in the obesity, cardiometabolic, or longevity categories were confirmed on FDA.gov in this seven-day window. Pending decisions still on watch this month include cytisinicline (smoking cessation, decision expected around June 20) and veligrotug for thyroid eye disease (PDUFA June 30). Source: FDA.gov; Drugs.com.
Source families: Nature Communications / UC San Diego / Medical News Today / MedicalXpress; British Journal of Clinical Pharmacology (Wiley); Business Wire / PR Newswire; Beauty Independent / Cosmetics Business; Calcalist / FinSMEs; Tech Startups venture roundup; Oura (The Pulse) / Modern Healthcare; TechRepublic / Samsung; Athletech News; Canyon Ranch; The Boston Globe; the5krunner; FDA.gov / Drugs.com / KRDO; and named conference organizers (HLTH Europe, Longevity Summit Dublin, The Longevity Show, NUS HLTI, WCGG). Verification cutoff: June 17, 2026.